On 25mg oral, four months in, and my results are closer to the low-dose injectable arm than to the numbers being quoted for 50mg.
The question I want answered is how much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly.
I have searched first, so if this is covered somewhere point me at it and I will read it.
Taking the question as asked, rather than the general version of it. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.
Dr.NateNeph said:Orforglipron is the more interesting oral story because it is not a peptide at all.
Dr.NateNeph has the substance of this right. The condition it depends on is worth stating. Worth adding that the tablet is taken daily, so a missed dose costs far less than a missed weekly injection. That is a genuine advantage nobody lists.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsmike_nyc said:On 25mg oral, four months in, and my results are closer to the low-dose injectable arm than to the numbers being quoted for 50mg.
Can confirm the pattern mike_nyc describes. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.
Happy to go further on any of that.
Clinical perspective, offered as context rather than as advice. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.